• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M

July 11, 2022 By Sean Whooley

Vertex Pharmaceuticals ViaCyteVertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million.

San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes.

Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. Just last week, the FDA lifted the clinical hold placed on the Phase 1/2 trial of VX-880.

“VX-880 has successfully demonstrated clinical proof of concept in [type 1 diabetes], and the acquisition of ViaCyte will accelerate our goal of transforming, if not curing [type 1 diabetes] by expanding our capabilities and bringing additional tools, technologies and assets to our current stem cell-based programs,” Vertex CEO and President Dr. Reshma Kewalramani said in a news release.

In the release, Vertex said its acquisition of ViaCyte provides it with complementary assets, capabilities and technologies including additional human stem cell lines, intellectual property around stem cell differentiation and good manufacturing practice (GMP) manufacturing facilities for cell-based therapies that could accelerate Vertex’s ongoing T1D programs.

Additionally, Vertex said the acquisition provides access to novel hypoimmune stem cell assets through the ViaCyte collaboration with CRISPR Therapeutics.

Vertex expects the $320 million cash acquisition to close later this year, subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

“ViaCyte’s commitment to finding a functional cure for [type 1 diabetes] is shared by Vertex, and this acquisition will allow Vertex to deploy ViaCyte’s tools, technologies and assets toward the development of Vertex’s multiple cell replacement therapy approaches designed to reduce the burden of millions of people living with [type 1 diabetes] worldwide,” VyaCyte President and CEO Michael Yang added.

Filed Under: Business/Financial News, Diabetes, Featured, Mergers & Acquisitions, Stem Cells Tagged With: Vertex Pharmaceuticals, ViaCyte

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS